Michael Kors Wallet Lilac
All of the statements in this press release that are not statements of historical facts constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon management's current plans and expectations and are subject to a number of risks and uncertainties which could cause actual results to differ materially from such statements. A discussion of the risks and uncertainties that can affect these statements is set forth in Halozyme's preliminary prospectus supplement and the accompanying prospectus filed with the SEC on February 3, 2014, together with the information incorporated by reference, under the heading "Risk Factors." Halozyme disclaims any intention or obligation to revise or update any forward looking statements, whether as a result of new information, future events, or otherwise.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Michael Kors Wallet Lilac Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA.
Safe Harbor Statement
Halozyme intends to use the net proceeds from this offering to fund research and development of proprietary programs, including the potential acceleration of the PEGPH20 program, and for other general corporate purposes.
An automatic shelf registration statement on Form S 3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective. A preliminary prospectus supplement relating to the offering has been filed with the SEC and a Michael Kors Bags Green
SAN DIEGO, Feb. 4, 2014 /PRNewswire/ , Inc.(NASDAQ: HALO) announced today the pricing of its previously announced underwritten public offering of 7,692,307 shares of its common stock at a public offering price of $13.00 per share. All of the shares in the offering are being sold by Halozyme. The offering is expected to close on February 10, 2014, subject to customary closing conditions. Morgan Securities LLC and Citigroup are acting as joint book running managers for the offering. Piper Jaffray Co. and BMO Capital Michael Kors Selma Navy
Of Bristol Myers Squibb Company (BMY)' Combo Cancer Trial Spooks Investors
Halozyme Therapeutics Inc Prices Public Offering Of Common Stock
Markets are acting as co managers for the offering.
, Inc. (HALO) Secures An Additional $20 Million Pace Michael Kors Handbags Uk
, Inc. (HALO) Taps New CEO What Biotech Experts Will Be Chirping About at JP Morgan This Week
SWOG Initiates Randomized Phase 2 Clinical Trial of , Inc. (HALO)'s PEGPH20 in Combination With Modified FOLFIRINOX for Advanced Pancreatic Cancer AmpliPhi Biosciences Corporation (APHB) Announces $18 Million Private Placement
final prospectus supplement relating to the offering will be filed with the SEC. Morgan Securities LLC, Attn: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803 9204; or Citigroup, Attn: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831 9146.
Help employers find you! Check out all the .
Investor and Media Contact:
Yale University Researchers Initiate Clinical Trial Evaluating , Inc. (HALO)'s Recombinant Hyaluronidase in Artificial Pancreas Study Epizyme (EPZM) Announces Pricing Of Public Offering Of Common Stock
SOURCE , Inc.
, Inc. (HALO) Announces Public Offering Of Common Stock Novo Nordisk A/S (NVO)'s IT Company To Look At Independent Listing
Michael Kors Wallet Lilac
Michael Kors Ava Bag Small
Michael Kors Wallet Cases For Iphone 6 Plus
Timberland 6 Inch Premium Boot Black Uk
Mens Timberland Tan Earthkeepers Heritage Boat 2 E Shoes
Michael Kors Bags Philippines
Michael Kors Purse Black And Tan
Timberland Earthkeepers Glastenbury Womens
Michael Kors Bags Violet
Michael Kors Purse Green
Michael Kors Bags With Chain
Michael Kors Rhea Backpack Small
Hot Pink Timberland Boots For Sale
Michael Kors Diaper Bags
Michael Kors Wallet Yellow
Black Suede Timberland Boots Ebay